Maureen E. Lane

1.3k total citations
26 papers, 816 citations indexed

About

Maureen E. Lane is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Maureen E. Lane has authored 26 papers receiving a total of 816 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Maureen E. Lane's work include Cancer, Hypoxia, and Metabolism (5 papers), Virus-based gene therapy research (4 papers) and Cancer-related Molecular Pathways (4 papers). Maureen E. Lane is often cited by papers focused on Cancer, Hypoxia, and Metabolism (5 papers), Virus-based gene therapy research (4 papers) and Cancer-related Molecular Pathways (4 papers). Maureen E. Lane collaborates with scholars based in United States, Canada and Malaysia. Maureen E. Lane's co-authors include Scott Wadler, Alla M. Rozenblit, Morris Edelman, Della Makower, Robert A. Moreau, P. Manjunath, David F. Yankelevitz, Isabelle Thérien, Maureen M. Ward and Barbara Hempstead and has published in prestigious journals such as Journal of Clinical Oncology, Biomaterials and Cancer Research.

In The Last Decade

Maureen E. Lane

26 papers receiving 803 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maureen E. Lane United States	15	368	307	167	135	98	26	816
Caterina Ieranò Italy	20	917 2.5×	546 1.8×	119 0.7×	74 0.5×	61 0.6×	34	1.4k
Н. В. Литвяков Russia	18	417 1.1×	405 1.3×	143 0.9×	63 0.5×	44 0.4×	110	955
С. В. Вторушин Russia	15	388 1.1×	298 1.0×	108 0.6×	44 0.3×	109 1.1×	78	841
Leonardo Mirandola United States	20	439 1.2×	606 2.0×	51 0.3×	79 0.6×	31 0.3×	58	1.1k
Chau P. Tran United States	9	344 0.9×	401 1.3×	332 2.0×	106 0.8×	48 0.5×	11	873
Elizabeth De Oliveira United States	11	686 1.9×	508 1.7×	137 0.8×	47 0.3×	106 1.1×	17	1.2k
Satyaki Sengupta United States	10	298 0.8×	1.5k 4.8×	309 1.9×	79 0.6×	134 1.4×	15	1.8k
Yoo-Joung Ko Canada	11	311 0.8×	364 1.2×	451 2.7×	79 0.6×	38 0.4×	18	943
Miriam Redrado Spain	20	518 1.4×	544 1.8×	177 1.1×	37 0.3×	65 0.7×	39	1.1k
Haiqing Luo China	13	319 0.9×	389 1.3×	144 0.9×	53 0.4×	31 0.3×	36	823

Countries citing papers authored by Maureen E. Lane

Since Specialization

Citations

This map shows the geographic impact of Maureen E. Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen E. Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen E. Lane more than expected).

Fields of papers citing papers by Maureen E. Lane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen E. Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen E. Lane. The network helps show where Maureen E. Lane may publish in the future.

Co-authorship network of co-authors of Maureen E. Lane

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen E. Lane. A scholar is included among the top collaborators of Maureen E. Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen E. Lane. Maureen E. Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fogelman, David R., Steven M. Townson, Gauri R. Varadhachary, et al.. (2018). A pilot study to assess the efficacy, safety, and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 36(4_suppl). TPS533–TPS533. 2 indexed citations

Kornhauser, Naomi, Amy D. Willis, Maureen M. Ward, et al.. (2017). A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results.. Journal of Clinical Oncology. 35(15_suppl). 2557–2557. 9 indexed citations

Stanton, Sasha E., Maureen M. Ward, Paul J. Christos, et al.. (2015). Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 15(1). 267–267. 56 indexed citations

DelNero, Peter, Maureen E. Lane, Scott S. Verbridge, et al.. (2015). 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. Biomaterials. 55. 110–118. 108 indexed citations

Ocean, Allyson J., Paul J. Christos, Joseph A. Sparano, et al.. (2014). Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Investigational New Drugs. 32(3). 542–548. 11 indexed citations

Niesvizky, Rubén, Tomer M. Mark, Maureen Ward, et al.. (2013). Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research. 19(6). 1534–1546. 20 indexed citations

Jain, Sarika, Jules Cohen, Maureen M. Ward, et al.. (2013). Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Annals of Oncology. 24(6). 1491–1498. 79 indexed citations

Jain, Sarika, Maureen M. Ward, Jennifer O’Loughlin, et al.. (2011). Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Research and Treatment. 132(1). 235–242. 27 indexed citations

Ocean, Allyson J., Paul J. Christos, Joseph A. Sparano, et al.. (2010). Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology. 68(2). 379–388. 23 indexed citations

10.

Cham, Matthew D., Maureen E. Lane, Claudia I. Henschke, & David F. Yankelevitz. (2008). Lung Biopsy: Special Techniques. Seminars in Respiratory and Critical Care Medicine. 29(4). 335–349. 38 indexed citations

11.

Lane, Maureen E., Jeanne M. Fahey, Nancy Hamel, et al.. (2007). In vivo synergy between oncolytic reovirus and gemcitibane in ras-mutated human HCT116 xenografts. Cancer Research. 67. 4812–4812. 4 indexed citations

12.

Ocean, Allyson J., Maureen E. Lane, Xiang Zhang, et al.. (2004). Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan. Journal of Clinical Oncology. 22(14_suppl). 9717–9717. 6 indexed citations

13.

Wadler, Scott, Jian Tan, Alla M. Rozenblit, et al.. (2003). Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.. Clinical Cancer Research. 9(1). 33–43. 27 indexed citations

14.

Makower, Della, Alla M. Rozenblit, Howard Kaufman, et al.. (2003). Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.. 9(2). 693–702. 109 indexed citations

15.

Yu, Bo, Maureen E. Lane, & Scott Wadler. (2002). SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochemical Pharmacology. 64(7). 1091–1100. 21 indexed citations

16.

Wadler, Scott, Della Makower, Alla M. Rozenblit, et al.. (2002). Clinical Applications of P53-Directed Gene Therapy. Tumori Journal. 1(6_suppl1). S21–S21. 1 indexed citations

17.

Yu, Bo, Maureen E. Lane, Richard G. Pestell, Chris Albanese, & Scott Wadler. (2000). Downregulation of Cyclin D1 Alters cdk 4- and cdk 2-Specific Phosphorylation of Retinoblastoma Protein. PubMed. 3(6). 352–359. 34 indexed citations

18.

Lane, Maureen E., Isabelle Thérien, Robert A. Moreau, & P. Manjunath. (1999). Heparin and High-Density Lipoprotein Mediate Bovine Sperm Capacitation by Different Mechanisms1. Biology of Reproduction. 60(1). 169–175. 59 indexed citations

19.

Cook, Jeffery R., et al.. (1989). Microporosity of the substratum regulates differentiation of MDCK cells in vitro. In Vitro Cellular & Developmental Biology - Plant. 25(10). 914–922. 32 indexed citations

20.

Rw, Talley, et al.. (1976). Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study.. PubMed. 60(7). 907–11. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact